Detalles de la búsqueda
1.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38620072
2.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38620092
3.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37363867
4.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38693677
5.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood
; 138(19): 1805-1816, 2021 11 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34086865
6.
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
Ann Hematol
; 102(11): 3083-3090, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37358640
7.
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Am J Hematol
; 2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38757754
8.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol
; 99(6): 1192-1195, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578022
9.
Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
Am J Hematol
; 96(12): E457-E460, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34591989
10.
Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Clin Cancer Res
; 28(19): 4203-4211, 2022 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35594173
11.
Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older.
Leuk Lymphoma
; 63(14): 3299-3306, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36120898
12.
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Lancet Haematol
; 9(10): e745-e755, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35988545
13.
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.
Nat Commun
; 12(1): 5395, 2021 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34518531
Resultados
1 -
13
de 13
1
Próxima >
>>